Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
BMC Complement Altern Med ; 14: 450, 2014 Nov 18.
Article in English | MEDLINE | ID: mdl-25407631

ABSTRACT

BACKGROUND: Caryocar brasiliense Camb (Pequi) is a typical Brazilian Cerrado fruit tree. Its fruit is used as a vitamin source for culinary purposes and as a source of oil for the manufacture of cosmetics. C. brasiliense supercritical CO2 extracts exhibit antimicrobial activity against the bacteria Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aureus and also possess antioxidant activity. This study was designed to evaluate the in vitro cytotoxicity and phototoxicity of the supercritical CO2 extract obtained from the leaves of this species. METHODS: In vitro cytotoxicity and phototoxicity of C. brasiliense supercritical CO2 extracts were assessed using a tetrazolium-based colorimetric assay (XTT) and Neutral Red methods. RESULTS: We found that the C. brasiliense (Pequi) extract obtained by supercritical CO2 extraction did not present cytotoxic and phototoxic hazards. CONCLUSIONS: This finding suggests that the extract may be useful for the development of cosmetic and/or pharmaceutical products.


Subject(s)
Anti-Bacterial Agents/adverse effects , Ericales/adverse effects , Fibroblasts/drug effects , Plant Extracts/adverse effects , Plant Leaves , 3T3 Cells , Animals , Anti-Bacterial Agents/pharmacology , Bacteria/drug effects , Brazil , Fruit , Mice , Plant Extracts/pharmacology
2.
J Med Food ; 16(3): 268-71, 2013 Mar.
Article in English | MEDLINE | ID: mdl-23444962

ABSTRACT

In this study, the ethanolic extract obtained from piquiá pulp was assessed for genotoxicity and oxidative stress by employing the micronucleus test in bone marrow and peripheral blood cells in addition to comet, thiobarbituric-acid-reactive substances (TBARS), and reduced glutathione assays in the liver, kidney, and heart. Additionally, phytochemical analyses were performed to identify and quantify the chemical constituents of the piquiá extract. Wistar rats were treated by gavage with an ethanolic extract from piquiá pulp (75 mg/kg body weight) for 14 days, and 24 h prior to euthanasia, they received an injection of saline or doxorubicin (15 mg/kg body weight, intraperoneally). The results demonstrated that piquiá extract at the tested dose was genotoxic but not mutagenic, and it increased the TBARS levels in the heart. Further studies are required to fully elucidate how the properties of ethanolic extract of piquiá pulp can affect human health.


Subject(s)
Ericales/adverse effects , Fruit/adverse effects , Heart/drug effects , Mutagens/adverse effects , Oxidative Stress , Plant Extracts/adverse effects , Animals , Cattle , Comet Assay , Glutathione/metabolism , Humans , Male , Mice , Micronucleus Tests , Myocardium/metabolism , Rats , Rats, Wistar , Thiobarbituric Acid Reactive Substances/metabolism
3.
Phytomedicine ; 6(3): 141-6, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10439477

ABSTRACT

The aim of this randomised double-blind multi-centre parallel group comparative study was to investigate the efficacy and tolerability of a new standardised fresh-plant extract obtained from the shoot tips of St. John's wort (Hypericum perforatum L.) in the treatment of mild to moderate depression. 348 out-patients (259 female, 89 male) with mild to moderate depression were recruted by 12 psychiatrc specialty practices and 26 general practices. The patients took during 6 weeks 3 times a day 1 tablet of a Hypericum preparation standardised to either 0.17 mg (114 patients), 0.33 mg (115 patients), or 1 mg (119 patients) total hypericin per day (Hyperiforce). The main outcome measure was the Hamilton Psychiatric Rating Scale for Depression; additional measures were the Hospital Anxiety and Depression Scale and the Clinical Global Impression. At the end of treatment, a reduction in the average Hamilton Depression score from an initial 16-17 to 8-9, i.e. a relative reduction of about 50%, was observed in all groups (280 patients, par protocol analysis). The response rates were 62%, 65% and 68%, respectively (348 patients, intention to treat analysis). Overall, the intergroup comparison revealed no significant differences. Tolerability was excellent, with mild adverse reactions probably causally related to the treatment occurring in only 7 of the 348 patients (2%). This Hypericum preparation is effective in all three doses and is well tolerated.


Subject(s)
Antidepressive Agents/therapeutic use , Depression/drug therapy , Ericales , Adult , Aged , Aged, 80 and over , Antidepressive Agents/administration & dosage , Antidepressive Agents/adverse effects , Depression/psychology , Double-Blind Method , Ericales/adverse effects , Female , Humans , Male , Middle Aged , Plant Extracts/administration & dosage , Plant Extracts/adverse effects , Plant Extracts/therapeutic use , Psychiatric Status Rating Scales
4.
Nurse Pract ; 24(6): 28, 31, 35-6 passim; quiz 47-9, 1999 Jun.
Article in English | MEDLINE | ID: mdl-10431295

ABSTRACT

The use of herbal or alternative therapies continues to increase each year. This article extensively reviews four of the more commonly used herbs and dietary supplements: ginkgo biloba, St. John's wort, saw palmetto, and soy. The pharmacology, precautions, therapeutic uses, and adverse effects for each of these therapies are discussed.


Subject(s)
Ericales/therapeutic use , Ginkgo biloba/therapeutic use , Glycine max/therapeutic use , Phytotherapy , Plants, Medicinal , Trees/therapeutic use , Ericales/adverse effects , Ginkgo biloba/adverse effects , Humans , Plant Extracts/administration & dosage , Plant Extracts/adverse effects , Plant Extracts/pharmacology , Glycine max/adverse effects , Time Factors
5.
J Geriatr Psychiatry Neurol ; 12(1): 7-10, 1999.
Article in English | MEDLINE | ID: mdl-10447148

ABSTRACT

There is increasing interest in and use of the herbal preparation St. John's wort. Hypericin, the major active ingredient, has many psychoactive properties. The agent is sold in the US as a nutritional supplement and is recommended for numerous conditions, including depression, anxiety, insomnia, and inflammation. We report a series of five cases of clinically diagnosed central serotonergic syndrome among elderly patients who combined prescription antidepressants with St. John's wort. Older adults are large consumers of both over-the-counter and prescription medications. They are particularly vulnerable to interactions between medications and products sold as nutritional or herbal supplements. St. John's wort requires further evaluation due to potential for drug interactions with central nervous system agents and for more definitive therapeutic indications.


Subject(s)
Antidepressive Agents/metabolism , Ericales/chemistry , Plants, Medicinal/chemistry , Aged , Aged, 80 and over , Antidepressive Agents/therapeutic use , Depressive Disorder/drug therapy , Drug Interactions , Ericales/adverse effects , Female , Herb-Drug Interactions , Humans , Male , Middle Aged , Plants, Medicinal/adverse effects
6.
Altern Ther Health Med ; 5(4): 40-9, 1999 Jul.
Article in English | MEDLINE | ID: mdl-10394673

ABSTRACT

The use of herbal medicine is widespread and growing, with as many as 3 in 10 Americans using botanical remedies in a given year. Because many herbal medicines have significant pharmacological activity, and thus potential adverse effects and drug interactions, healthcare professionals must be familiar with this therapeutic modality. This article summarizes the history and current use of plant-based medicine and highlights the evidence of the risks and benefits associated with 6 plants: echinacea, garlic, ginger, ginkgo, St John's wort, and valerian. Therapies outside the medical mainstream tend to suffer from a dearth of research and critical evaluation. Critics and supporters alike note the conceptual and practical difficulties in studying many complementary and alternative therapies such as acupuncture, homeopathy, and meditation. Herbal medicine, however, lends itself well to standard evaluation methods. This article summarizes and evaluates evidence from randomized controlled trials and meta-analyses. We present the results of meta-analyses and subsequent randomized controlled trials for garlic and St John's wort; a comprehensive critical review and subsequent randomized controlled trials for ginkgo; and summaries of all identified randomized controlled trials for echinacea, ginger, and valerian.


Subject(s)
Plants, Medicinal/adverse effects , Ericales/adverse effects , Garlic/adverse effects , Ginkgo biloba/adverse effects , Humans , Plant Extracts/adverse effects , Risk Assessment , Valerian/adverse effects , Zingiberales/adverse effects
9.
Minn Med ; 82(5): 29-31, 1999 May.
Article in English | MEDLINE | ID: mdl-10337137

ABSTRACT

The use of medicinal herbs has increased over the past few years, and psychotropic herbs are among the most popular on the market. Patients and physicians may assume these products are safe; however, dietary supplements are not subject to the rigorous testing required for prescription medications. Problems that may occur with the use of psychotropic herbs include overuse or abuse, side effects, and herb-drug interactions. Ma huang, St. John's wort, and kava are examples of readily available herbs with the potential for negative effects. Physicians should improve their knowledge of these products so they can provide reliable information to their patients.


Subject(s)
Plants, Medicinal/adverse effects , Psychotropic Drugs/adverse effects , Ephedrine/adverse effects , Ericales/adverse effects , Humans , Kava , Plant Extracts/adverse effects
10.
Int J Clin Pharmacol Ther ; 37(3): 111-9, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10190758

ABSTRACT

OBJECTIVE: The primary purpose of this article is to review the existing literature concerning the therapeutic uses, adverse effects, and possible drug interactions of St. John's wort (Hypericum perforatum) as compared to other antidepressant medications. METHODS: Reference material was obtained through database searches with time restrictions of 1985 to the present. Studies selected were those written in the English language which compared the role of St. John's wort, tricyclic antidepressants, monoamine oxidase inhibitors, and serotonin-selective reuptake inhibitors in the treatment of depression. Other studies were selected based on their evaluation of the safety and efficacy of St. John's wort as an antidepressant for a minimum of four weeks. RESULTS: A review of existing literature recognized nine clinical trials that reported the efficacy of St. John's wort as compared to placebo and to other antidepressant medications. Of these nine, four controlled studies were chosen based upon their large patient populations and their consistency in brand and dosage of St. John's wort used. These four studies demonstrated that St. John's wort was as effective as other antidepressant medications and more effective than placebo, as the clinical symptoms of depression greatly decreased upon administration of H. perforatum. The side-effect profile of H. perforatum at this time appears to be superior to any current U.S.-approved antidepressant medication. CONCLUSIONS: From the existing literature, St. John's wort appears to be a safe and effective alternative in the treatment of depression. Tricylic antidepressants and monoamine oxidase inhibitors can produce serious cardiac side-effects, such as tachycardia and postural hypotension, and many unwanted anticholinergic side-effects, including dry mouth and constipation. St. John's wort has proven to be free of any cardiac, as well as anticholinergic, side-effects normally seen with antidepressant medications. Based upon limited studies, St. John's wort appears to be an acceptable alternative to traditional antidepressant therapy, although trials on a larger scale are warranted in this area. Hypericum is available to the lay public as an over-the-counter preparation and may be misused if not fully understood.


Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder/therapy , Ericales/therapeutic use , Phytotherapy , Antidepressive Agents/adverse effects , Antidepressive Agents, Tricyclic/adverse effects , Antidepressive Agents, Tricyclic/therapeutic use , Clinical Trials as Topic , Contraindications , Drug Interactions , Ericales/adverse effects , Humans , Monoamine Oxidase Inhibitors/adverse effects , Monoamine Oxidase Inhibitors/therapeutic use , Serotonin Syndrome , Selective Serotonin Reuptake Inhibitors/adverse effects , Selective Serotonin Reuptake Inhibitors/therapeutic use
11.
J Ren Nutr ; 9(2): 58-62, 1999 Apr.
Article in English | MEDLINE | ID: mdl-10089260

ABSTRACT

The independent use of nutritional supplements has increased dramatically over the past several years. St. John's Wort for the treatment of depression, chromium for improvement of abnormal glucose and insulin regulation, and garlic for hypercholesterolemia, are among the more popular nutritional supplements being used by the population at large for their respective conditions. Depression, diabetes, and hypercholesterolemia are common to the renal patient. However, the efficacy of St. John's Wort, chromium, and garlic for these problems in the patient with impaired renal function is not known. This article reviews the pharmacology, efficacy, safety, and pharmokinetics of these three food supplements in the nonrenal patient. There are encouraging data suggesting successful treatment in the otherwise normal individual. However, clinical studies examining the safety of these three supplements for the treatment of depression, diabetes, and hypercholesterolemia in the patient with renal disease are lacking and preclude recommendation of their use.


Subject(s)
Depression/therapy , Diabetic Nephropathies/therapy , Dietary Supplements , Hypercholesterolemia/therapy , Kidney Diseases/therapy , Depression/complications , Ericales/adverse effects , Ericales/therapeutic use , Garlic/therapeutic use , Humans , Hypercholesterolemia/complications , Kidney Diseases/complications , Phytotherapy , Picolinic Acids/adverse effects , Picolinic Acids/pharmacokinetics , Picolinic Acids/therapeutic use , Plants, Medicinal
12.
Am Fam Physician ; 59(5): 1239-45, 1999 Mar 01.
Article in English | MEDLINE | ID: mdl-10088878

ABSTRACT

A growing number of Americans are using herbal products for preventive and therapeutic purposes. The manufacturers of these products are not required to submit proof of safety and efficacy to the U.S. Food and Drug Administration before marketing. For this reason, the adverse effects and drug interactions associated with herbal remedies are largely unknown. Ginkgo biloba extract, advertised as improving cognitive functioning, has been reported to cause spontaneous bleeding, and it may interact with anticoagulants and antiplatelet agents. St. John's wort, promoted as a treatment for depression, may have monoamine oxidase-inhibiting effects or may cause increased levels of serotonin, dopamine and norepinephrine. Although St. John's wort probably does not interact with foods that contain tyramine, it should not be used with prescription antidepressants. Ephedrine-containing herbal products have been associated with adverse cardiovascular events, seizures and even death. Ginseng, widely used for its purported physical and mental effects, is generally well tolerated, but it has been implicated as a cause of decreased response to warfarin. Physicians must be alert for adverse effects and drug interactions associated with herbal remedies, and they should ask all patients about the use of these products.


Subject(s)
Plants, Medicinal/adverse effects , Drug Interactions , Ephedrine/adverse effects , Ericales/adverse effects , Ginkgo biloba/adverse effects , Herb-Drug Interactions , Humans , Kava , Panax/adverse effects , Patient Education as Topic , Plant Extracts/adverse effects , Teaching Materials , United States , United States Food and Drug Administration
14.
Eur J Clin Pharmacol ; 54(8): 589-94, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9860144

ABSTRACT

UNLABELLED: This paper provides a systematic review of adverse drug reactions (ADRs) associated with the use of extracts of the herb St. John's wort (Hypericum perfbratum L.) for the treatment of mild to moderate depression. METHODS: Searches of four computerized literature databases were performed for records of (ADRs). Manufacturers of hypericum products, the international drug monitoring centre of the World Health Organization (WHO) and the national drug safety monitoring bodies of Germany and the United Kingdom were also contacted for information. RESULTS: Information on (ADRs) originates from case reports, clinical trials, post-marketing surveillance and drug monitoring studies. Collectively, the data suggest that hypericum is well tolerated, with an incidence of adverse reactions similar to that of placebo. The most common adverse effects are gastrointestinal symptoms, dizziness/confusion and tiredness/sedation. A potential serious adverse effect is photosensitivity, but this appears to occur extremely rarely. CONCLUSIONS: Hypericum has an encouraging safety profile. However, as most of the current data originate from short-term investigations, more long-term studies are desirable.


Subject(s)
Antidepressive Agents/adverse effects , Ericales/adverse effects , Photosensitizing Agents/adverse effects , Plant Extracts/adverse effects , Drug Monitoring , Humans , Randomized Controlled Trials as Topic
19.
Med J Aust ; 169(11-12): 583-6, 1998.
Article in English | MEDLINE | ID: mdl-9887899

ABSTRACT

St John's wort (SJW) was introduced into Australia during the 1880s for medicinal purposes, but was subsequently declared a noxious weed. There is now a resurgence of interest in the therapeutic properties of this herb. In particular, use of SJW as an antidepressant has increased in recent months owing to reports of its effectiveness and safety. Nevertheless, the controlled trials available have limitations. Increasing use of SJW in the community poses a variety of questions. For example, should medical practitioners become more knowledgeable about the effects and interactions of alternative remedies? What are the ethical and medical implications of "antidepressant" prescribing by non-medical persons? Who is to fund further research and treatment studies? How can quality of SJW preparations be guaranteed?


Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder/therapy , Ericales/therapeutic use , Phytotherapy , Adult , Australia , Complementary Therapies , Ericales/adverse effects , Humans
SELECTION OF CITATIONS
SEARCH DETAIL
...